Literature DB >> 8593024

Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia.

R Bohte1, H Mattie, P J van den Broek.   

Abstract

After an oral dose of 500 mg of azithromycin in patients with community-acquired pneumonia, their serum concentrations ranged between 0.06 and 0.25 mg/liter during the first 12 hours; the calculated percentages of unbound drug varied between 45 and 86%. This study shows that in these patients, the total levels of azithromycin in serum are lower than those expected and that the percentage of bound drug is clinically irrelevant.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8593024      PMCID： PMC163034          DOI： 10.1128/AAC.39.12.2801

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

2.  Saturation of the tubular excretion of beta-lactam antibiotics.

Authors:  J W Bins; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Pneumococcal bacteraemia during a recent decade.

Authors:  A Kuikka; J Syrjänen; O V Renkonen; V V Valtonen
Journal:  J Infect       Date:  1992-03       Impact factor: 6.072

4.  Activity of erythromycin and clindamycin in an experimental Staphylococcus aureus infection in normal and granulocytopenic mice. A comparative in vivo and in vitro study.

Authors:  J J Hoogeterp; H Mattie; R van Furth
Journal:  Scand J Infect Dis       Date:  1993

5.  The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia.

Authors:  J Myburgh; G J Nagel; E Petschel
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

6.  Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations--Huntington, WVa, and Stockholm, Sweden.

Authors:  A Ortqvist; M Kalin; I Julander; M A Mufson
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

Review 7.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

8.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191
  8 in total
  3 in total

1.  Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

Authors:  Ighovwerha Ofotokun; Jeffrey L Lennox; Molly E Eaton; James C Ritchie; Kirk A Easley; Svetlana E Masalovich; Mary C Long; Edward P Acosta
Journal:  J Clin Pharmacol       Date:  2011-01-05       Impact factor: 3.126

2.  Binding and drug displacement study of colchicine and bovine serum albumin in presence of azithromycin using multispectroscopic techniques and molecular dynamic simulation.

Authors:  Tanveer A Wani; Ahmed H Bakheit; Abdulrahman A Al-Majed; Nojood Altwaijry; Anwar Baquaysh; Ashwaq Aljuraisy; Seema Zargar
Journal:  J Mol Liq       Date:  2021-03-18       Impact factor: 6.165

3.  Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.

Authors:  Karen Rowland Yeo; Mian Zhang; Xian Pan; Alice Ban Ke; Hannah M Jones; David Wesche; Lisa M Almond
Journal:  Clin Pharmacol Ther       Date:  2020-07-16       Impact factor: 6.903
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.